DOT1L regulates dystrophin expression and is critical for cardiac function

Area of Science:

• Molecular Biology
• Genetics
• Cardiology

Background:

• Histone methylation, specifically H3K79, regulates gene expression.
• DOT1L (disruptor of telomeric silencing like) is the mammalian homolog of yeast DOT1.
• Germline disruption of Dot1L in mice leads to embryonic lethality.

Purpose of the Study:

• To investigate the role of DOT1L in cardiomyocyte function and its potential link to dilated cardiomyopathy (DCM).
• To elucidate the molecular mechanism by which DOT1L regulates cardiomyocyte viability.

Main Methods:

• Cardiac-specific knockout of Dot1L in mice.
• Phenotypic analysis of knockout mice, including mortality, cardiac function, and histology.
• Mechanistic studies involving gene expression analysis and rescue experiments with Dystrophin (Dmd).
• Analysis of human gene expression data from DCM patients.

Main Results:

• Cardiac-specific Dot1L knockout mice exhibited increased mortality, chamber dilation, cardiomyocyte death, systolic dysfunction, and conduction abnormalities, mimicking DCM.
• DOT1L regulates cardiomyocyte viability by controlling Dystrophin (Dmd) transcription and the stability of the Dystrophin-glycoprotein complex.
• Expression of a miniDmd construct partially rescued DCM phenotypes.
• DOT1L was found to be down-regulated in human idiopathic DCM samples.

Conclusions:

• DOT1L-mediated H3K79 methylation is critical for cardiomyocyte function and preventing DCM.
• Dystrophin (Dmd) is a key mediator of DOT1L function in the heart.
• Down-regulation of DOT1L in human DCM suggests its potential role in the pathogenesis of the disease.
• This study provides novel insights into the molecular mechanisms of DCM and potential therapeutic targets.